Dialectic Therapeutics – UF Innovate https://innovate.research.ufl.edu Building business on innovation Fri, 21 Nov 2025 17:49:19 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://innovate.research.ufl.edu/wp-content/uploads/favicon-blue_1.png Dialectic Therapeutics – UF Innovate https://innovate.research.ufl.edu 32 32 Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PR Newswire) https://innovate.research.ufl.edu/dialectic-therapeutics-announces-dosing-of-first-patient-in-platinum-resistant-ovarian-cancer/ Fri, 21 Nov 2025 17:48:57 +0000 https://innovate.research.ufl.edu/?p=20722 UF startup Dialectic Therapeutics, Inc., a clinical-stage biotechnology company developing innovative anti-cancer drugs, announced that patient dosing is underway in a clinical trial led by the renowned Drs. Elizabeth Stover, Joyce Liu, and Ursula Matulonis from the Dana-Farber Cancer Institute. Dr. Matulonis previously served as the Principal Investigator for the study that led to a recent FDA approval in platinum-resistant ovarian cancer (PROC).

 

Read more about Dialectic Therapeutics Announces Dosing of First Patient in Platinum-Resistant Ovarian Cancer (PROC).

]]> The Fibrolamellar Cancer Foundation Establishes Partnership With Dialectic Therapeutics https://innovate.research.ufl.edu/dialectic-therapeutics-partnership/ Mon, 21 Apr 2025 00:00:00 +0000 https://scaddev1.com/dialectic-therapeutics-partnership/ Effort will support a new clinical trial for fibrolamellar carcinoma, a rare cancer that primarily impacts children and young adults

UF startup Dialectic Therapeutics, in partnership with the Fibrolamellar Cancer Foundation (FCF), will supply the experimental drug DT2216 for a clinical trial involving fibrolamellar patients. Under the agreement, FCF will fund the production of the DT2216 necessary to support the trial. The Foundation’s funding of the company’s manufacturing costs of the drug was crucial to ensure the launch of the new clinical trial this year.

Dialectic Therapeutics, Inc. is a Texas-based clinical stage biotechnology company focused on creating innovative new technologies to treat cancer. DT2216 is their first-in-class anticancer agent that targets a protein called BCL-XL, the most commonly over-expressed anti-apoptotic protein in cancer.

Read more about The Fibrolamellar Cancer Foundation Establishes Partnership With Dialectic Therapeutics. ]]> Researchers and UF Innovate | Accelerate startup founders find Highly Effective Therapeutic Strategy for Small-Cell Lung Cancer https://innovate.research.ufl.edu/protac-mediated-dual-degradation-of-bcl-xl-and-bcl-2-is-a-highly-effective-therapeutic-strategy-in-small-cell-lung-cancer/ Mon, 04 Mar 2024 00:00:00 +0000 https://scaddev1.com/protac-mediated-dual-degradation-of-bcl-xl-and-bcl-2-is-a-highly-effective-therapeutic-strategy-in-small-cell-lung-cancer/ Researchers and founders of UF startup company Dialectic Therapeutics have discovered a new way to treat small-cell lung cancer (SCLC). Medicinal Chemistry professor Guangrong Zheng, Ph.D. and former UF professor of Pharmacodynamics Daohong Zhou co-founded the company, which is finding innovative new ways to treat cancer.

Alongside other researchers, they found the proteins BCL-XL and BCL-2 can be targeted to help treat SCLC. Previous treatments targeted these proteins using navitoclax, an anti-cancer drug, which resulted in platelet toxicity.

This new treatment degrades these proteins over time, prohibiting them from contributing to tumor growth and reducing potential side-effects.

Dialectic Therapeutics is based in Dallas, TX and develops BCL-XL/2 PROTACs to treat cancer.

Read more about: Protac-Mediated Dual Degradation of Bcl-XL and Bcl-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. ]]> Dialectic Therapeutics Announces DT2216 Has Received Orphan Drug Designation From the FDA for the Treatment of T-Cell Lymphoma https://innovate.research.ufl.edu/dialectic-therapeutics-orphan-drug-fda-treatment-t-cell-lymphoma/ Mon, 14 Mar 2022 00:00:00 +0000 https://scaddev1.com/dialectic-therapeutics-orphan-drug-fda-treatment-t-cell-lymphoma/ UF startup Dialectic Therapeutics, Inc. (Dialectic®), announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DT2216 for the treatment of T-cell lymphoma.  DT2216 is Dialectic’s first generation compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD™) technology platform.

“This is an important milestone in the development of DT2216, our lead APTaD™ compound. The FDA’s decision to grant orphan drug designation underscores our belief that DT2216 could be a promising therapeutic for T-cell lymphoma patients” said Dr. David Genecov, Dialectic’s President and Chief Executive Officer. “There is a critical unmet need for people diagnosed with this rare cancer, in which current approved therapies have relatively low response rates”.

Normal T-cells require BCL-XL expression to survive thymic selection during their development. After thymic selection BCL-XL normal T-cells no longer express BCL-XL. However, many T-cell lymphomas re-express BCL-XL as a mechanism of their neoplastic transformation and permits their continued survival as a malignancy. Studies have demonstrated the importance of BCL-XL in T-cell lymphoma survival. Dialectic has shown that DT2216 is an effective treatment for T-cell lymphoma in preclinical studies.

Learn more about Dialectic Therapeutics Announces DT2216 Has Received Orphan Drug Designation From the FDA for the Treatment of T-Cell Lymphoma. ]]> Dialectic Therapeutics Announces First-in-Human Dose in Phase 1 Clinical Trial Evaluating DT2216, Its First Generation Antiapoptotic Protein Targeted Degradation (APTaD™) Compound, in Patients With Relapsed or Refractory Malignancies https://innovate.research.ufl.edu/dialectic-therapeutics-first-in-human-dose/ Thu, 07 Oct 2021 00:00:00 +0000 https://scaddev1.com/dialectic-therapeutics-first-in-human-dose/ UF startup Dialectic Therapeutics, Inc., a Texas-based clinical-stage biotechnology company focused on creating innovative new technologies to treat cancer, announced the dosing of the first patient in a first-in-human, dose-escalation Phase 1 trial evaluating DT2216, the first generation compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD™) technology, in patients with relapsed or refractory solid tumor and hematologic malignancies.

“Advancing our first-generation APTaD DT2216 into the clinic is the culmination of a tremendous amount foundational research conducted by our scientific team supported by extensive preclinical studies. This also marks the first time a protein degrader targeting the antiapoptotic BCL family of proteins has been administered in humans. We believe DT2216 has the potential to be a first-in-class anticancer agent targeting BCL-XL, the most commonly over-expressed antiapoptotic protein in cancer, as a single agent and in combination with chemotherapy regimens and other therapeutics. We look forward to learning more about the safety, tolerability and anti-tumor activity of DT2216 in this trial and presenting future data,” said Dr. David Genecov, Dialectic’s president and chief executive officer. “With DT2216 in the clinic, we look forward to leveraging our novel APTaD technology platform to advance the next generations of our degrader compounds.”

Learn more about Dialectic Therapeutics Announces First-in-Human Dose in Phase 1 Clinical Trial Evaluating DT2216, Its First Generation Antiapoptotic Protein Targeted Degradation (APTaD™) Compound, in Patients With Relapsed or Refractory Malignancies.
Dialectic Therapeutics Receives FDA Clearance of IND Application for for Its Lead Product Candidate To Treat Cancer
]]> Dialectic Therapeutics Receives FDA Clearance of IND Application for for Its Lead Product Candidate To Treat Cancer https://innovate.research.ufl.edu/dialectic-fda-clearence/ Thu, 04 Mar 2021 00:00:00 +0000 https://scaddev1.com/dialectic-fda-clearence/ UF startup Dialectic Therapeutics, Inc., a Texas-based biotechnology company focused on creating innovative new technologies to treat cancer, announced that the U.S. Food and Drug Administration (FDA) has concluded that Dialectic may proceed with its clinical investigation for its lead product candidate, DT2216, a unique compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD) technology. In pre-clinical studies supported through a Seed Award from the Cancer Prevention & Research Institute of Texas (CPRIT), DT2216 selectively induces cancer cells to degrade B-cell lymphoma extra-large, or BCL-XL, stimulating the cells to commit suicide or become more susceptible to chemotherapy.

Learn more about Dialectic Therapeutics Receives FDA Clearance of IND Application for for Its Lead Product Candidate To Treat Cancer. ]]>